Medovex Corp. to Present at the LD Micro Invitational Conference on June 2, 2015
ATLANTA, GA -- (Marketwired) -- 05/11/15 -- Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, announced today that CEO Jarrett Gorlin and President and COO Patrick Kullmann will be presenting at the LD Micro Invitational on Tuesday, June 2nd at 12:00 PM PDT / 3:00 PM EDT.
"We are glad to welcome the Medovex team to the Invitational," commented Chris Lahiji, President of LD Micro."
The presentation will be webcast and available at the company's website in the investor relations section, or at: http://wsw.com/webcast/ldmicro8/mdvx/
The conference will be held at the Luxe Sunset Bel Air Hotel, and will feature 185 companies in the small / micro-cap space.
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care delivery combined with cost effectiveness. Medovex's first pipeline product, the DenerveX™ device and generator, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available surgical options. To learn more about Medovex Corp., visit www.medovex.com
Safe Harbor Statement:
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Medovex believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including the risks that the Streamline ISS product may not prove to be efficient, that the Company will not be able to form a satisfactory U.S. marketing relationship, and that the Company's product may not prove effective in increasing the safety of intra-hospital patient transport, as well as the risks identified in the Company's filings with the Securities and Exchange Commission (the "SEC"), including but not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Source: Medovex Corp.
Released May 11, 2015